Stem definition | Drug id | CAS RN |
---|---|---|
uridine derivatives used as antiviral agents and as antineoplastics | 2478 | 3056-17-5 |
Dose | Unit | Route |
---|---|---|
80 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 83 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 39 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.95 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 82 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.67 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 8.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 24, 1994 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pregnancy | 387.99 | 37.45 | 123 | 3294 | 29454 | 50572253 |
Drug resistance | 382.74 | 37.45 | 110 | 3307 | 18879 | 50582828 |
Viral mutation identified | 369.81 | 37.45 | 68 | 3349 | 1561 | 50600146 |
Virologic failure | 295.88 | 37.45 | 56 | 3361 | 1508 | 50600199 |
Lipodystrophy acquired | 279.32 | 37.45 | 52 | 3365 | 1277 | 50600430 |
Lactic acidosis | 271.57 | 37.45 | 97 | 3320 | 33258 | 50568449 |
Immune reconstitution inflammatory syndrome | 215.53 | 37.45 | 54 | 3363 | 5462 | 50596245 |
Pathogen resistance | 174.82 | 37.45 | 46 | 3371 | 5643 | 50596064 |
Foetal exposure during pregnancy | 158.21 | 37.45 | 62 | 3355 | 27297 | 50574410 |
Caesarean section | 144.29 | 37.45 | 50 | 3367 | 15589 | 50586118 |
Abortion induced | 135.21 | 37.45 | 42 | 3375 | 9302 | 50592405 |
Mitochondrial toxicity | 134.84 | 37.45 | 23 | 3394 | 335 | 50601372 |
Portal hypertension | 116.61 | 37.45 | 30 | 3387 | 3362 | 50598345 |
Hypertriglyceridaemia | 84.97 | 37.45 | 26 | 3391 | 5465 | 50596242 |
Hyperlactacidaemia | 81.09 | 37.45 | 21 | 3396 | 2412 | 50599295 |
Acquired gene mutation | 80.23 | 37.45 | 17 | 3400 | 814 | 50600893 |
Pregnancy on contraceptive | 76.24 | 37.45 | 17 | 3400 | 1035 | 50600672 |
Stillbirth | 74.63 | 37.45 | 24 | 3393 | 5928 | 50595779 |
Exposure during pregnancy | 74.29 | 37.45 | 63 | 3354 | 120952 | 50480755 |
Normal newborn | 71.88 | 37.45 | 24 | 3393 | 6667 | 50595040 |
Abortion spontaneous | 71.78 | 37.45 | 41 | 3376 | 41731 | 50559976 |
Live birth | 70.19 | 37.45 | 30 | 3387 | 16378 | 50585329 |
Premature delivery | 65.64 | 37.45 | 32 | 3385 | 23631 | 50578076 |
Fat tissue increased | 62.78 | 37.45 | 13 | 3404 | 556 | 50601151 |
Blood lactic acid increased | 59.85 | 37.45 | 20 | 3397 | 5565 | 50596142 |
Lipoatrophy | 57.84 | 37.45 | 11 | 3406 | 302 | 50601405 |
Premature rupture of membranes | 55.51 | 37.45 | 18 | 3399 | 4562 | 50597145 |
Premature baby | 54.48 | 37.45 | 26 | 3391 | 18311 | 50583396 |
Blood HIV RNA increased | 40.48 | 37.45 | 9 | 3408 | 540 | 50601167 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lipodystrophy acquired | 906.84 | 22.46 | 195 | 6479 | 2899 | 29564954 |
Mitochondrial toxicity | 678.23 | 22.46 | 147 | 6527 | 2264 | 29565589 |
Eyelid ptosis | 527.64 | 22.46 | 139 | 6535 | 5047 | 29562806 |
Immune reconstitution inflammatory syndrome | 410.73 | 22.46 | 125 | 6549 | 7677 | 29560176 |
Diplopia | 358.29 | 22.46 | 129 | 6545 | 13389 | 29554464 |
Progressive external ophthalmoplegia | 323.96 | 22.46 | 72 | 6602 | 1245 | 29566608 |
Virologic failure | 231.43 | 22.46 | 64 | 6610 | 2783 | 29565070 |
Foetal exposure during pregnancy | 183.77 | 22.46 | 107 | 6567 | 33760 | 29534093 |
Drug resistance | 181.02 | 22.46 | 91 | 6583 | 21449 | 29546404 |
Blood lactic acid increased | 137.58 | 22.46 | 51 | 6623 | 5715 | 29562138 |
Ophthalmoplegia | 132.93 | 22.46 | 37 | 6637 | 1645 | 29566208 |
Lipoatrophy | 132.74 | 22.46 | 29 | 6645 | 460 | 29567393 |
Hypertriglyceridaemia | 131.60 | 22.46 | 53 | 6621 | 7422 | 29560431 |
Viral mutation identified | 127.06 | 22.46 | 39 | 6635 | 2449 | 29565404 |
Hepatic fibrosis | 112.82 | 22.46 | 38 | 6636 | 3214 | 29564639 |
Osteonecrosis | 110.22 | 22.46 | 56 | 6618 | 13463 | 29554390 |
Pathogen resistance | 101.04 | 22.46 | 45 | 6629 | 8071 | 29559782 |
Lactic acidosis | 88.57 | 22.46 | 65 | 6609 | 30182 | 29537671 |
Portal hypertension | 80.09 | 22.46 | 30 | 6644 | 3456 | 29564397 |
Hyperlipidaemia | 79.53 | 22.46 | 44 | 6630 | 12546 | 29555307 |
Kaposi's sarcoma | 77.54 | 22.46 | 21 | 6653 | 841 | 29567012 |
Dyslipidaemia | 70.32 | 22.46 | 32 | 6642 | 6029 | 29561824 |
Facial wasting | 70.30 | 22.46 | 14 | 6660 | 137 | 29567716 |
Hyperlactacidaemia | 68.71 | 22.46 | 25 | 6649 | 2653 | 29565200 |
Drug-induced liver injury | 66.69 | 22.46 | 48 | 6626 | 21607 | 29546246 |
Blood triglycerides increased | 60.24 | 22.46 | 37 | 6637 | 12797 | 29555056 |
Acquired gene mutation | 52.88 | 22.46 | 17 | 6657 | 1241 | 29566612 |
CD4 lymphocytes decreased | 52.77 | 22.46 | 18 | 6656 | 1580 | 29566273 |
Blood bilirubin unconjugated increased | 52.07 | 22.46 | 14 | 6660 | 545 | 29567308 |
Premature baby | 47.99 | 22.46 | 36 | 6638 | 17244 | 29550609 |
Off label use | 47.61 | 22.46 | 6 | 6668 | 300794 | 29267059 |
Mitochondrial myopathy | 43.86 | 22.46 | 10 | 6664 | 194 | 29567659 |
Dysphagia | 40.99 | 22.46 | 56 | 6618 | 54870 | 29512983 |
Meningitis cryptococcal | 40.80 | 22.46 | 16 | 6658 | 2084 | 29565769 |
Progressive multifocal leukoencephalopathy | 40.56 | 22.46 | 25 | 6649 | 8694 | 29559159 |
Multiple-drug resistance | 40.28 | 22.46 | 19 | 6655 | 3881 | 29563972 |
Trisomy 21 | 39.35 | 22.46 | 11 | 6663 | 496 | 29567357 |
Enophthalmos | 37.47 | 22.46 | 6 | 6668 | 13 | 29567840 |
Basedow's disease | 36.09 | 22.46 | 7 | 6667 | 59 | 29567794 |
Pinealoblastoma | 34.18 | 22.46 | 8 | 6666 | 175 | 29567678 |
Hypotension | 32.94 | 22.46 | 3 | 6671 | 194351 | 29373502 |
Nodular regenerative hyperplasia | 31.89 | 22.46 | 10 | 6664 | 673 | 29567180 |
Treatment failure | 31.14 | 22.46 | 40 | 6634 | 36899 | 29530954 |
Cytomegalovirus chorioretinitis | 31.07 | 22.46 | 15 | 6659 | 3223 | 29564630 |
Heart transplant rejection | 30.47 | 22.46 | 11 | 6663 | 1140 | 29566713 |
Pulmonary tuberculosis | 29.78 | 22.46 | 16 | 6658 | 4299 | 29563554 |
Gynaecomastia | 29.44 | 22.46 | 20 | 6654 | 8197 | 29559656 |
Fall | 29.32 | 22.46 | 3 | 6671 | 177175 | 29390678 |
Hepatic cirrhosis | 29.23 | 22.46 | 25 | 6649 | 14419 | 29553434 |
Fanconi syndrome acquired | 28.78 | 22.46 | 12 | 6662 | 1830 | 29566023 |
Lipohypertrophy | 27.76 | 22.46 | 7 | 6667 | 211 | 29567642 |
Lagophthalmos | 27.52 | 22.46 | 6 | 6668 | 94 | 29567759 |
Low set ears | 27.27 | 22.46 | 8 | 6666 | 429 | 29567424 |
Hepatomegaly | 27.18 | 22.46 | 20 | 6654 | 9297 | 29558556 |
Neuropathy peripheral | 26.52 | 22.46 | 53 | 6621 | 70974 | 29496879 |
Mycobacterium avium complex infection | 26.37 | 22.46 | 12 | 6662 | 2257 | 29565596 |
Drug ineffective | 26.34 | 22.46 | 26 | 6648 | 363144 | 29204709 |
Pneumocystis jirovecii pneumonia | 26.01 | 22.46 | 25 | 6649 | 16754 | 29551099 |
Glucose tolerance impaired | 23.99 | 22.46 | 12 | 6662 | 2782 | 29565071 |
Protrusion tongue | 23.69 | 22.46 | 6 | 6668 | 184 | 29567669 |
Central pain syndrome | 23.66 | 22.46 | 5 | 6669 | 67 | 29567786 |
Atypical mycobacterial infection | 23.55 | 22.46 | 8 | 6666 | 693 | 29567160 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lipodystrophy acquired | 1173.56 | 23.73 | 231 | 8367 | 3796 | 64486338 |
Mitochondrial toxicity | 847.67 | 23.73 | 165 | 8433 | 2541 | 64487593 |
Immune reconstitution inflammatory syndrome | 680.92 | 23.73 | 183 | 8415 | 12287 | 64477847 |
Eyelid ptosis | 530.25 | 23.73 | 142 | 8456 | 9383 | 64480751 |
Drug resistance | 439.82 | 23.73 | 168 | 8430 | 34934 | 64455200 |
Virologic failure | 417.30 | 23.73 | 96 | 8502 | 3370 | 64486764 |
Progressive external ophthalmoplegia | 367.14 | 23.73 | 73 | 8525 | 1254 | 64488880 |
Diplopia | 338.32 | 23.73 | 129 | 8469 | 26636 | 64463498 |
Viral mutation identified | 335.97 | 23.73 | 80 | 8518 | 3266 | 64486868 |
Pregnancy | 290.62 | 23.73 | 108 | 8490 | 20757 | 64469377 |
Lactic acidosis | 260.99 | 23.73 | 138 | 8460 | 61272 | 64428862 |
Lipoatrophy | 181.50 | 23.73 | 36 | 8562 | 609 | 64489525 |
Portal hypertension | 180.93 | 23.73 | 56 | 8542 | 6163 | 64483971 |
Pathogen resistance | 149.55 | 23.73 | 58 | 8540 | 12485 | 64477649 |
Ophthalmoplegia | 134.82 | 23.73 | 37 | 8561 | 2665 | 64487469 |
Acquired gene mutation | 131.41 | 23.73 | 34 | 8564 | 1952 | 64488182 |
Hepatic fibrosis | 124.43 | 23.73 | 41 | 8557 | 5511 | 64484623 |
Osteonecrosis | 112.88 | 23.73 | 61 | 8537 | 28168 | 64461966 |
Abortion induced | 107.27 | 23.73 | 38 | 8560 | 6350 | 64483784 |
Hyperlactacidaemia | 105.46 | 23.73 | 35 | 8563 | 4809 | 64485325 |
Dyslipidaemia | 104.03 | 23.73 | 41 | 8557 | 9201 | 64480933 |
Hypertriglyceridaemia | 103.07 | 23.73 | 43 | 8555 | 11162 | 64478972 |
Caesarean section | 99.47 | 23.73 | 42 | 8556 | 11232 | 64478902 |
CD4 lymphocytes decreased | 88.33 | 23.73 | 26 | 8572 | 2409 | 64487725 |
Blood lactic acid increased | 79.45 | 23.73 | 35 | 8563 | 10366 | 64479768 |
Facial wasting | 77.72 | 23.73 | 13 | 8585 | 78 | 64490056 |
Pulmonary tuberculosis | 74.10 | 23.73 | 30 | 8568 | 7214 | 64482920 |
Neuropathy peripheral | 73.00 | 23.73 | 84 | 8514 | 117441 | 64372693 |
Drug-induced liver injury | 72.39 | 23.73 | 56 | 8542 | 47587 | 64442547 |
Kaposi's sarcoma | 70.45 | 23.73 | 17 | 8581 | 732 | 64489402 |
Multiple-drug resistance | 70.22 | 23.73 | 28 | 8570 | 6474 | 64483660 |
Pregnancy on contraceptive | 69.53 | 23.73 | 17 | 8581 | 774 | 64489360 |
Foetal exposure during pregnancy | 69.01 | 23.73 | 25 | 8573 | 4451 | 64485683 |
Fat tissue increased | 68.45 | 23.73 | 17 | 8581 | 826 | 64489308 |
Normal newborn | 60.00 | 23.73 | 24 | 8574 | 5593 | 64484541 |
Meningitis cryptococcal | 58.61 | 23.73 | 20 | 8578 | 2989 | 64487145 |
Nodular regenerative hyperplasia | 58.07 | 23.73 | 15 | 8583 | 855 | 64489279 |
Abortion spontaneous | 57.69 | 23.73 | 38 | 8560 | 25105 | 64465029 |
Blood bilirubin unconjugated increased | 57.28 | 23.73 | 15 | 8583 | 902 | 64489232 |
Hyperlipidaemia | 55.84 | 23.73 | 36 | 8562 | 22940 | 64467194 |
Stillbirth | 54.92 | 23.73 | 20 | 8578 | 3613 | 64486521 |
Blood triglycerides increased | 51.96 | 23.73 | 32 | 8566 | 18834 | 64471300 |
Progressive multifocal leukoencephalopathy | 50.40 | 23.73 | 31 | 8567 | 18201 | 64471933 |
Live birth | 49.81 | 23.73 | 26 | 8572 | 11178 | 64478956 |
Hepatomegaly | 47.42 | 23.73 | 29 | 8569 | 16853 | 64473281 |
Off label use | 47.34 | 23.73 | 13 | 8585 | 632793 | 63857341 |
Premature delivery | 47.33 | 23.73 | 30 | 8568 | 18559 | 64471575 |
Pancreatitis | 46.37 | 23.73 | 48 | 8550 | 59559 | 64430575 |
Mitochondrial myopathy | 45.64 | 23.73 | 10 | 8588 | 279 | 64489855 |
Fall | 43.97 | 23.73 | 3 | 8595 | 416823 | 64073311 |
Gynaecomastia | 41.96 | 23.73 | 19 | 8579 | 5997 | 64484137 |
Basedow's disease | 41.28 | 23.73 | 9 | 8589 | 245 | 64489889 |
Stevens-Johnson syndrome | 40.91 | 23.73 | 35 | 8563 | 34214 | 64455920 |
Dysphagia | 39.23 | 23.73 | 59 | 8539 | 106753 | 64383381 |
Tuberculoma of central nervous system | 39.16 | 23.73 | 10 | 8588 | 544 | 64489590 |
Pinealoblastoma | 39.06 | 23.73 | 7 | 8591 | 66 | 64490068 |
Pneumocystis jirovecii pneumonia | 38.76 | 23.73 | 31 | 8567 | 27603 | 64462531 |
Pain | 38.43 | 23.73 | 13 | 8585 | 553498 | 63936636 |
Treatment failure | 37.98 | 23.73 | 61 | 8537 | 116755 | 64373379 |
Tuberculosis | 35.60 | 23.73 | 22 | 8576 | 13016 | 64477118 |
Ascites | 34.61 | 23.73 | 42 | 8556 | 61959 | 64428175 |
Gene mutation | 33.49 | 23.73 | 12 | 8586 | 2070 | 64488064 |
Blood HIV RNA increased | 33.41 | 23.73 | 11 | 8587 | 1473 | 64488661 |
Mycobacterium avium complex infection | 32.50 | 23.73 | 14 | 8584 | 3926 | 64486208 |
Enophthalmos | 32.48 | 23.73 | 6 | 8592 | 68 | 64490066 |
Lymphadenopathy | 31.72 | 23.73 | 35 | 8563 | 46651 | 64443483 |
Hepatosplenomegaly | 31.44 | 23.73 | 15 | 8583 | 5328 | 64484806 |
Oesophageal varices haemorrhage | 30.28 | 23.73 | 13 | 8585 | 3616 | 64486518 |
Hyperbilirubinaemia | 30.19 | 23.73 | 24 | 8574 | 21181 | 64468953 |
Hepatic cirrhosis | 29.63 | 23.73 | 26 | 8572 | 26272 | 64463862 |
Cytomegalovirus chorioretinitis | 29.54 | 23.73 | 14 | 8584 | 4898 | 64485236 |
Hepatitis B | 28.90 | 23.73 | 16 | 8582 | 7729 | 64482405 |
Hepatic steatosis | 27.84 | 23.73 | 27 | 8571 | 30980 | 64459154 |
Gamma-glutamyltransferase increased | 27.29 | 23.73 | 33 | 8565 | 48477 | 64441657 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 26.92 | 23.73 | 8 | 8590 | 765 | 64489369 |
Hepatic failure | 26.89 | 23.73 | 35 | 8563 | 55359 | 64434775 |
Premature rupture of membranes | 26.67 | 23.73 | 12 | 8586 | 3732 | 64486402 |
Molluscum contagiosum | 26.26 | 23.73 | 7 | 8591 | 451 | 64489683 |
Oligohydramnios | 25.44 | 23.73 | 11 | 8587 | 3113 | 64487021 |
Treatment noncompliance | 25.15 | 23.73 | 30 | 8568 | 43452 | 64446682 |
Liver disorder | 24.80 | 23.73 | 33 | 8565 | 53318 | 64436816 |
Placental insufficiency | 24.74 | 23.73 | 8 | 8590 | 1012 | 64489122 |
Fanconi syndrome acquired | 24.66 | 23.73 | 10 | 8588 | 2411 | 64487723 |
Hypotension | 24.63 | 23.73 | 10 | 8588 | 380964 | 64109170 |
Viral load increased | 24.40 | 23.73 | 10 | 8588 | 2477 | 64487657 |
Fatigue | 24.38 | 23.73 | 39 | 8559 | 748691 | 63741443 |
Meningitis tuberculous | 24.07 | 23.73 | 8 | 8590 | 1103 | 64489031 |
None
Source | Code | Description |
---|---|---|
ATC | J05AF04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleoside and nucleotide reverse transcriptase inhibitors |
ATC | J05AR07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA MoA | N0000009947 | Nucleoside Reverse Transcriptase Inhibitors |
FDA EXT | N0000175459 | Nucleoside Analog |
FDA EPC | N0000175462 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
CHEBI has role | CHEBI:22587 | antiviral agents |
CHEBI has role | CHEBI:35221 | antimetabolite |
CHEBI has role | CHEBI:59897 | reverse transcriptase inhibitors |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D009676 | Noxae |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Steatosis of liver | contraindication | 197321007 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Chronic pancreatitis | contraindication | 235494005 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Peripheral nerve disease | contraindication | 302226006 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.3 | acidic |
pKa2 | 13.25 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
100MG | ZERIT XR | BRISTOL MYERS SQUIBB | N021453 | Dec. 31, 2002 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7135465 | Feb. 18, 2023 | METHOD FOR TREATING HIV-1 INFECTION |
37.5MG | ZERIT XR | BRISTOL MYERS SQUIBB | N021453 | Dec. 31, 2002 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7135465 | Feb. 18, 2023 | METHOD FOR TREATING HIV-1 INFECTION |
50MG | ZERIT XR | BRISTOL MYERS SQUIBB | N021453 | Dec. 31, 2002 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7135465 | Feb. 18, 2023 | METHOD FOR TREATING HIV-1 INFECTION |
75MG | ZERIT XR | BRISTOL MYERS SQUIBB | N021453 | Dec. 31, 2002 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7135465 | Feb. 18, 2023 | METHOD FOR TREATING HIV-1 INFECTION |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Reverse transcriptase/RNaseH | Enzyme | INHIBITOR | EC50 | 7.30 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | WOMBAT-PK | |||||||
Reverse transcriptase | Enzyme | IC50 | 7.22 | CHEMBL |
ID | Source |
---|---|
D00445 | KEGG_DRUG |
4020865 | VANDF |
C0164662 | UMLSCUI |
CHEBI:63581 | CHEBI |
CHEMBL991 | ChEMBL_ID |
DB00649 | DRUGBANK_ID |
D018119 | MESH_DESCRIPTOR_UI |
18283 | PUBCHEM_CID |
6775 | INN_ID |
BO9LE4QFZF | UNII |
203748 | RXNORM |
1468 | MMSL |
159782 | MMSL |
5512 | MMSL |
d03773 | MMSL |
004502 | NDDF |
108690008 | SNOMEDCT_US |
386895008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-515 | CAPSULE | 15 mg | ORAL | ANDA | 25 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-516 | CAPSULE | 20 mg | ORAL | ANDA | 25 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-517 | CAPSULE | 30 mg | ORAL | ANDA | 25 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-518 | CAPSULE | 40 mg | ORAL | ANDA | 25 sections |
stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53104-0111 | FOR SOLUTION | 1 mg | ORAL | ANDA | 26 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0594 | CAPSULE | 40 mg | ORAL | ANDA | 25 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0595 | CAPSULE | 40 mg | ORAL | ANDA | 25 sections |
ZERIT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0656 | CAPSULE, GELATIN COATED | 20 mg | ORAL | NDA | 24 sections |
ZERIT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0657 | CAPSULE, GELATIN COATED | 30 mg | ORAL | NDA | 24 sections |
ZERIT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0795 | CAPSULE, GELATIN COATED | 40 mg | ORAL | NDA | 24 sections |
Stavudine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0852 | CAPSULE | 20 mg | ORAL | ANDA | 30 sections |